Giant asteroid swarm near Venus could pose ‘invisible threat' to Earth, scientists warn
A swarm of giant city-killer asteroids hiding near Venus poses an 'invisible threat' to life on Earth, astronomers have warned in a new study.
These space rocks, known as co-orbital asteroids, tag along with Venus as it circles the Sun and likely originated from debris in the main asteroid belt between Mars and Jupiter.
There are around 20 such asteroids so far discovered around Venus, and each of them is likely larger than about 140 metres (460 ft) in size – large enough that they could potentially wipe out an area the size of a city if they impacted the Earth.
All but one of the known asteroids tag along with Venus on very elongated trajectories, hinting there's likely an observational bias in how scientists have found them.
Scientists suspect there could be many more such undiscovered asteroids around Venus with lower 'eccentricities' – or deviations from a perfect circle – that are obscured from our view due to the Sun's glare.
'This is most likely caused by observational biases since asteroids with larger eccentricities may approach the Earth and are easier to detect,' they wrote.
These hidden asteroids may also change their trajectories relative to Venus, bringing them closer to the Earth.
While they do not pose any immediate risk, a close approach to Earth could pull them onto a collision course with our planet and threaten life over the coming millennia, according to a yet-to-be peer-reviewed study.
In the study, researchers conducted computer simulations to determine whether any potential hidden asteroid circling Venus and obscured from our view may threaten Earth in the future.
Scientists made replica computer models of the already known co-orbital rocks around Venus, but with different orbits relative to Venus and observed how they behaved over 36,000 years.
'There is a range of orbits with eccentricities lower than 0.38 for which Venus' co-orbitals can pose a collisional hazard to Earth,' scientists wrote.
However, it is hard to estimate exactly what risk they pose in colliding with Earth since the exact number of co-orbitals with Venus is unknown, they say.
Researchers hope the Rubin Observatory may play a role in detecting some of these asteroids in the future 'during favourable configurations'.
'Space missions based on Venus' orbits may be instrumental in detecting Venus' co-orbitals at low eccentricities,' they concluded.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
3 hours ago
- The Independent
These mysterious dark ‘streaks' on Mars aren't what scientists initially believed
Mysterious dark streaks first observed on Mars in the 1970s are not what many believed they were. Scientists now say the curious features that stretch for hundreds of meters down Martian slopes were likely signs of wind and dust activity — not water. 'A big focus of Mars research is understanding modern-day processes on Mars — including the possibility of liquid water on the surface,' Adomas Valantinas, a postdoctoral researcher at Brown University, said in a statement. 'Our study reviewed these features but found no evidence of water. Our model favors dry formation processes.' Valantinas and the University of Bern's Valentin Bickel coauthored the research which was recently published in the journal Nature Communications. To reach these conclusions, the researchers used a machine learning algorithm to catalog as many of the odd streaks as they could, creating a first-of-its-kind- global Martian map containing some 500,000 from more than 86,000 high-resolution images from NASA's Mars Reconnaissance Orbiter. Then, they compared their map to databases and catalogs of other factors, including temperature, wind speed, hydration, and rock slide activity. They looked for any correlations over hundreds of thousands of cases. The authors found that the ominous streaks that don't last for decades, known as recurring slope lineae or RSLs, are not generally associated with factors that suggest a liquid or frost origin. Those factors might include a specific slope orientation, high surface temperature fluctuations, and high humidity. The features were more likely to form in places with above-average wind speed and dust deposition. That points to a dry origin of formation, and they seem to show up in the same locations during the warmest periods of the Martian year before mysteriously vanishing. They concluded that the older slope streaks, which run down cliff faces and crater walls, most likely form when dust suddenly slides off slopes following seismic activity, winds, or even the shockwaves from meteoroid impacts. The streaks appear most often near recent impact craters, where shockwaves may shake the surface dust loose. The shorter-lived ones are typically found in places where dust devils or rockfalls are frequent. 'There were statistically significant correlations between new impact sites and the appearance of nearby slope streaks in certain regions, supporting this view,' NASA said. Previously, some had interpreted those streaks as liquid flows. It's possible that small amounts of water could mix with enough salt to create a flow on the frozen Martian surface, Brown University noted. The red planet was once more temperate, and there is water under the surface of Mars. Others believed they were triggered by dry process. These results cast new doubt on slope streaks and RSLs as habitable environments. 'That's the advantage of this big data approach,' Valantinas said. 'It helps us to rule out some hypotheses from orbit before we send spacecraft to explore.'
BBC News
10 hours ago
- BBC News
Scientists create the 'world's smallest violin'
A team of scientists have created the 'world's smallest violin' - which is tinier than a speck of dust and needs a microscope to see it!The micro-violin was created using nanotechnology by a team at Loughborough measures 35 microns long and 13 microns wide - a micron is one millionth of a metre - for comparison a human hair is around 17 to 180 microns the tiny violin is just an image and not a playable instrument, so it cannot be officially confirmed as the world's smallest violin, the university said. The tiny violin was created to test the abilities of the university's new nanolithography system, which allows researchers to build and study tiny structures."Though creating the world's smallest violin may seem like fun and games, a lot of what we've learned in the process has actually laid the groundwork for the research we're now undertaking," said Professor Kelly Morrison, Head of the Physics department at Loughborough University."Our nanolithography system allows us to design experiments that probe materials in different ways – using light, magnetism, or electricity – and observe their responses."Once we understand how materials behave, we can start applying that knowledge to develop new technologies, whether it's improving computing efficiency or finding new ways to harvest energy," she said. How did they make it? To create the violin the researchers coated a tiny chip with two layers of gel-like material called a resist, before placing it under a nano-sculpting the machine uses a heated, needle-like tip to "write" very precise patterns on the nanoscale - in this case a violin shape - in a process called thermal scanning probe that a thin layer of platinum was poured into the carved out pattern to leave behind the finished whole process takes around three hours, but the research team's final version took several months to make, as they tested different techniques to get the best result.
Daily Mail
10 hours ago
- Daily Mail
Subtle warning signs of 'silent disease' 16m Americans are living with and don't know
Nearly 16 million people have the most deadly type of liver disease, yet 80 percent of them have no idea. About five percent of adults worldwide have metabolic dysfunction-associated steatohepatitis (MASH) a serious liver condition caused by fat buildup, inflammation, and scarring. It's the most dangerous type of fatty liver disease MASH triggers liver scarring, which can progress to cirrhosis, and significantly increases the risk of heart disease, chronic kidney disease, and liver cancer. Just one in five Americans with the condition are actually diagnosed. Most patients do not experience symptoms until the damage is irreversible, making it a 'silent disease'. However, as the condition progresses, individuals may experience fatigue, pain or discomfort in the upper right belly, unexplained weight loss, weakness, and in some cases, jaundice (yellowing of the skin and eyes). A coalition of researchers from the US, Europe, and South Africa said that MASH-related liver failure and other complications, including deaths, are becoming more severe and common. The scientists behind the report, published in The Lancet Regional Health Europe, are calling for a doubling in MASH diagnosis rates from the 2022 level, about 13 percent (the current rate is just under 20 percent). They estimated that about 2.6 million people in the US, UK, Germany, and France have been diagnosed with MASH. But if testing were adequately improved and scaled up to become more accessible and commonplace, that figure could balloon to 6.1 million. People with type 2 diabetes, obesity, and heart disease should be prioritized for blood work and other screening tests, which will need to skyrocket from about two million to 36 million. Follow-up testing also needs to jump by nearly 1,300 percent to meet patient needs, and in more settings than liver clinics, such as family doctors' offices, and with diabetes and heart doctors. People with diabetes are especially prone to liver damage leading to MASH. Around 30 to 60 percent of diabetics also have MASH. Obesity is another leading risk factor, with estimates suggesting that 75 percent of overweight people and 90 percent with obesity will develop the condition. People with MASH also have a tripled risk of also developing heart disease, including coronary artery disease, stroke, and heart failure, compared to people without the condition. MASH diagnosis is poised for a major shift, mirroring past breakthroughs in chronic disease management. With new treatments approved and others on the horizon, the focus now turns to fixing systemic roadblocks. Currently, limited access to non-invasive tests and reliance on specialists leave most cases undetected until late stages. MASH arises from a cascade of liver damage typically linked to a buildup of fat in the liver, which triggers inflammation that damages liver cells and activates scar-forming cells. What was once healthy liver tissue becomes stiff, progressively crippling the liver's ability to detoxify blood. Though this is often painless until the damage becomes too severe to be reversed. If caught early, people can live normal lifespans with MASH. Lifestyle changes - eating a healthier diet, exercising regularly, and losing between five and 10 percent of one's body weight - can slow down the progression of MASH and repair some of the damage. Doctors may prescribe resmetirom, the first FDA-approved medication for MASH, to work hand-in-hand with those lifestyle changes. But severe damage can cause deadly conditions that cut a person's life drastically short. 'Each late-stage MASH diagnosis represents a missed opportunity for earlier intervention to prevent disease progression, threatening worse [liver] and [non-liver] outcomes for people living with the condition and greater costs for individuals, health systems, and societies,' researchers told a Barcelona medical conference this week. The solution requires concrete changes from moving diagnostics to implementing automated tools in electronic records. The researchers said that success in improving diagnostics goes beyond devising better tests. A fundamental reworking of methods of care is needed that catches at-risk patients before irreversible damage occurs. 'Paradigm shifts do not occur in a vacuum, but arise when leaps in science, technology, and innovation are coupled with changes in perception and understanding within a community,' they said. 'A confluence of factors in 2024 and expected drug approvals in many European countries in 2025 point to a near term tipping point for MASH diagnoses; nonetheless, focused and sustained efforts are needed to turn such opportunities into reality.'
